It occurred to me over the weekend that most major CVOT trials publish a "Rationale and Design" paper in advance of trial completion. Often these come out after enrollment is complete and baseline data is done being collected. Although Kausik Ray recently presented the full baseline data and trial design poster at AHA last month, we have yet to see "Rationale and Design" publication for apabetalone in BETonMACE as has been published for other major trials including, but not limited to, ACCELERATE, EMPA-REG OUTCOMES, FOURIER, ODYSSEY, CANTOS, CANVAS and REDUCE-IT. I wonder if Resverlogix and the Clinical Steering Committee have this in the queue. It would be great exposure. I wouldn't be surprised to see this come out any day now.